sufentanil sublingual 30 mcg tablet

DRUG2 trials

Sponsors

Talphera, Inc, University Hospital, Clermont-Ferrand

Conditions

Moderate-to-severe Acute PainPain Management

Phase 3

Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain

CompletedNCT02447848

Talphera, IncModerate-to-severe Acute Pain

Start: 2015-10-31End: 2016-07-31Updated: 2017-10-19

Management of Moderate to Severe Monotraumatic Pain With Sublingual Sufentanil in an Emergency Situation.

RecruitingNCT06917651

University Hospital, Clermont-FerrandPain Management

Start: 2025-04-22End: 2027-04-22Target: 300Updated: 2026-04-28